tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

SPYR Updates Shareholders on Plans and Objectives for 2017

SPYR Updates Shareholders on Plans and Objectives for 2017

DENVER, February 2017 — SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, and in the restaurant industry, today provides its shareholders with an update on its plans and objectives for the year 2017.

SPYR’s overarching goal for 2017 and beyond is to become a premier, diversified mobile games publisher, deriving revenue from games in various genres and appealing to multiple demographics.

Pocket Starships

SPYR’s main focus in 2016 ...

Read More →
0

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 12, 2016

All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...

Read More →
0

PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principle Investigator

Paper with Oncology and pills. Medical concept.

LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the first article in a series of Q&A articles that will be conducted with some of the key team members of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s first Q&A article is with Dr. Matthias Löhr of the famed ...

Read More →
0

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 1, 2016

Company Aiming to Produce 6-Month Breakthrough Data

PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer after the FDA granted its request for a pre-IND (Investigational New Drug) meeting. A host of oncologists, clinicians and scientists that represent PharmaCyte will now sit down with the U.S. regulatory agency to gain valuable insight that will assist them in filing an ...

Read More →
0

SPYR Targets Worldwide Audience for Pocket Starships as Asian Market Continues Solid Growth

SPYR Targets Worldwide Audience for Pocket Starships as Asian Market Continues Solid Growth

Written by Ι Stock Market Media — November 17, 2016

In 2016, the global games market grew to almost $100 billion according to Newzoo’s Global Games Market Report. In that report, China and the Asia-Pacific region account for almost half of the total revenue ($46.6 billion). SPYR, Inc. (OTCQB: SPYR) recognizes that getting its flagship MMO game Pocket Starships into that region and sharing in the revenue as that space continues to grow, should serve its shareholders well. SPYR recently added a video ...

Read More →
0

PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial

PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial

Written by Ι Stock Market Media — November 16, 2016

PharmaCyte Biotech (OTCQB: PMCB) has arrived at the door of U.S. FDA and awaits a pre-IND meeting with the agency. After years of surrounding its signature live-cell encapsulation technology, Cell-in-a-Box®, with some of the brightest minds in pancreatic cancer and fine-tuning its therapy and clinical trial design, the small biotech has reached the final test before it can begin its pivotal clinical trial in advanced pancreatic cancer.

PharmaCyte made two recent announcements that would ...

Read More →
0
Page 4 of 31 «...23456...»
ContactUs.com ContactUs.com